Localized scleroderma

Common Name(s)

Localized scleroderma

Localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. Collagen is a protein normally present in our skin that provides structural support. However, when too much collagen is made, the skin becomes stiff and hard. Localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. Internal organs are not affected by localized scleroderma, and localized scleroderma can never progress to the systemic form of the disease. Often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. For some people, localized scleroderma is serious and disabling.

There are two generally recognized types of localized scleroderma: morphea and linear.

 

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Localized scleroderma" for support, advocacy or research.

Logo
Raynaud's & Scleroderma Ireland

• To improve the lives of patients, their families and carers by providing support, advice and information. • To increase the awareness of Raynaud’s and Scleroderma amongst healthcare professionals, Government and Statutory agencies and the general public. • To work in partnership with appropriate healthcare professionals and agencies to promote and co-ordinate the attainment of the objectives of the strategy. • Maintain a working environment that fosters communication, teamwork and diversity among all members of staff- permanent, temporary and voluntary

Last Updated: 6 May 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Localized scleroderma" for support, advocacy or research.

Logo
Raynaud's & Scleroderma Ireland

• To improve the lives of patients, their families and carers by providing support, advice and information. • To increase the awareness of Raynaud’s and Scleroderma amongst healthcare professionals, Government and Statutory agencies and the general public. • To work in partnership with appropriate healthcare professionals and agencies to promote and co-ordinate the attainment of the objectives of the strategy. • Maintain a working environment that fosters communication, teamwork and diversity among all members of staff- permanent, temporary and voluntary

http://www.irishraynauds.com

Last Updated: 6 May 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Localized scleroderma" returned 48 free, full-text research articles on human participants. First 3 results:

Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma.
 

Author(s): Kelsey E Magee, Christina E Kelsey, Katherine L Kurzinski, Jonhan Ho, Logan R Mlakar, Carol A Feghali-Bostwick, Kathryn S Torok

Journal: Arthritis Res. Ther.. 2013 ;15(6):R188.

 

The purpose of this study was to evaluate the presence and levels of interferon-gamma inducible protein-10 (IP-10) in the plasma and skin of pediatric localized scleroderma (LS) patients compared to those of healthy pediatric controls and to determine if IP-10 levels correlate to ...

Last Updated: 6 Mar 2014

Go To URL
Implantation of autologous fat globules in localized scleroderma and idiopathic lipoatrophy--report of five patients.
 

Author(s): Tiago Pina Zanelato, Giovana Marquesini, Paula Tavares Colpas, Renata Ferreira Magalhães, Aparecida Machado de Moraes

Journal: An Bras Dermatol. ;88(6 Suppl 1):120-3.

 

A large number of diseases may cause Atrophic skin disorders are caused by a large number of diseases, some of them idiopathic and others inflammatory, in which there is loss of volume of body segments. Localized scleroderma is a rare inflammatory dermatosis, manifested by atrophic ...

Last Updated: 18 Dec 2013

Go To URL
The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population.
 

Author(s): Christina E Kelsey, Kathryn S Torok

Journal: J. Am. Acad. Dermatol.. 2013 Aug;69(2):214-20.

 

Lack of agreement on how to accurately capture disease outcomes in localized scleroderma (LS) has hindered the development of efficacious treatment protocols. The LS Cutaneous Assessment Tool (LoSCAT), consisting of the modified LS Skin Severity Index (mLoSSI) and the LS Damage Index, ...

Last Updated: 22 Jul 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Localized scleroderma" returned 7 free, full-text review articles on human participants. First 3 results:

Pediatric scleroderma: systemic or localized forms.
 

Author(s): Kathryn S Torok

Journal: Pediatr. Clin. North Am.. 2012 Apr;59(2):381-405.

 

Pediatric scleroderma includes 2 major groups of clinical entities, systemic sclerosis (SSc) and localized scleroderma (LS). Although both share a common pathophysiology, their clinical manifestations differ. LS is typically confined to the skin and underlying subcutis, with up to ...

Last Updated: 7 May 2012

Go To URL
Cytokine profiles in localized scleroderma and relationship to clinical features.
 

Author(s): Katherine Kurzinski, Kathryn S Torok

Journal: Cytokine. 2011 Aug;55(2):157-64.

 

Localized scleroderma (LS) is a disfiguring autoimmune disease of the skin and underlying tissue that mainly affects the pediatric population. Inflammation of the tissue leads to fibrosis and atrophy, causing physical and psychological disability that can continue throughout childhood ...

Last Updated: 29 Jun 2011

Go To URL
Pathogenesis and treatment modalities of localized scleroderma.
 

Author(s): Greta Valančienė, Daiva Jasaitienė, Skaidra Valiukevičienė

Journal: Medicina (Kaunas). 2010 ;46(10):649-56.

 

Localized scleroderma is a chronic inflammatory disease primarily of the dermis and subcutaneous fat that ultimately leads to a scar-like sclerosis of connective tissue. The disorder manifests as various plaques of different shape and size with signs of skin inflammation, sclerosis, ...

Last Updated: 11 Mar 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma
 

Status: Recruiting

Condition Summary: Localized Scleroderma

 

Last Updated: 9 Sep 2014

Go to URL
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
 

Status: Recruiting

Condition Summary: Scleroderma, Localized; Morphea; Frontal Linear Scleroderma en Coup de Sabre; Scleroderma, Circumscribed; Scleroderma, Linear

 

Last Updated: 2 Dec 2014

Go to URL
Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea
 

Status: Recruiting

Condition Summary: Scleroderma, Localized; Morphea; Scleroderma, Circumscribed

 

Last Updated: 2 Dec 2014

Go to URL